http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 17:58:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+10++Filed+by%3A+Peri+Jonathan/26933070.html si-local-file:///var/storage/secattach/20260814/26933070.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+10++Filed+by%3A+Peri+Jonathan/26933070.html Fri, 14 Aug 2026 17:58:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+10++Filed+by%3A+Peri+Jonathan/26933070.html si-local-file:///var/storage/secattach/20260814/26933070.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+10++Filed+by%3A+Peri+Jonathan/26933070.html Fri, 14 Aug 2026 17:58:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+10++Filed+by%3A+Peri+Jonathan/26933070.html si-local-file:///var/storage/secattach/20260814/26933070.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+10++Filed+by%3A+Peri+Jonathan/26933070.html Fri, 14 Aug 2026 17:58:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+10++Filed+by%3A+Peri+Jonathan/26933070.html si-local-file:///var/storage/secattach/20260814/26933070.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+10++Filed+by%3A+Peri+Jonathan/26933070.html Fri, 14 Aug 2026 17:58:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26932885.html si-local-file:///var/storage/secattach/20260814/26932885.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26932885.html Fri, 14 Aug 2026 17:25:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26932885.html si-local-file:///var/storage/secattach/20260814/26932885.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26932885.html Fri, 14 Aug 2026 17:25:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26932885.html si-local-file:///var/storage/secattach/20260814/26932885.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26932885.html Fri, 14 Aug 2026 17:25:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26932885.html si-local-file:///var/storage/secattach/20260814/26932885.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26932885.html Fri, 14 Aug 2026 17:25:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Jun+30/26931828.html si-local-file:///var/storage/secattach/20260814/26931828.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Jun+30/26931828.html Fri, 14 Aug 2026 16:40:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Jun+30/26931828.html si-local-file:///var/storage/secattach/20260814/26931828.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Jun+30/26931828.html Fri, 14 Aug 2026 16:40:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Jun+30/26931828.html si-local-file:///var/storage/secattach/20260814/26931828.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Jun+30/26931828.html Fri, 14 Aug 2026 16:40:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Jun+30/26931828.html si-local-file:///var/storage/secattach/20260814/26931828.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Jun+30/26931828.html Fri, 14 Aug 2026 16:40:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+14/26931796.html si-local-file:///var/storage/secattach/20260814/26931796.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+14/26931796.html Fri, 14 Aug 2026 16:39:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+14/26931796.html si-local-file:///var/storage/secattach/20260814/26931796.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+14/26931796.html Fri, 14 Aug 2026 16:39:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+14/26931796.html si-local-file:///var/storage/secattach/20260814/26931796.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+14/26931796.html Fri, 14 Aug 2026 16:39:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+14/26931796.html si-local-file:///var/storage/secattach/20260814/26931796.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+14/26931796.html Fri, 14 Aug 2026 16:39:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html <div class="xn-content"> <p class="prntac"><i><money>$7.1 Million</money> in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR</i> <i>^®</i></p><p class="prntac"><i><money>$17 million</money> in cash and cash equivalents as of <chron>June 30, 2026</chron></i></p><p class="prntac"><i>Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended <chron>June 30, 2026</chron>, and provided a business update, including progress at http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html Fri, 14 Aug 2026 16:30:00 -0400 A.24478717 A.50216726 CTOR CTXR O.11391251 O.21612337 O.41511844 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html <div class="xn-content"> <p class="prntac"><i><money>$7.1 Million</money> in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR</i> <i>^®</i></p><p class="prntac"><i><money>$17 million</money> in cash and cash equivalents as of <chron>June 30, 2026</chron></i></p><p class="prntac"><i>Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended <chron>June 30, 2026</chron>, and provided a business update, including progress at http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html Fri, 14 Aug 2026 16:30:00 -0400 A.24478717 A.50216726 CTOR CTXR O.11391251 O.21612337 O.41511844 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html <div class="xn-content"> <p class="prntac"><i><money>$7.1 Million</money> in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR</i> <i>^®</i></p><p class="prntac"><i><money>$17 million</money> in cash and cash equivalents as of <chron>June 30, 2026</chron></i></p><p class="prntac"><i>Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended <chron>June 30, 2026</chron>, and provided a business update, including progress at http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html Fri, 14 Aug 2026 16:30:00 -0400 A.24478717 A.50216726 CTOR CTXR O.11391251 O.21612337 O.41511844 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html <div class="xn-content"> <p class="prntac"><i><money>$7.1 Million</money> in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR</i> <i>^®</i></p><p class="prntac"><i><money>$17 million</money> in cash and cash equivalents as of <chron>June 30, 2026</chron></i></p><p class="prntac"><i>Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended <chron>June 30, 2026</chron>, and provided a business update, including progress at http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html Fri, 14 Aug 2026 16:30:00 -0400 A.24478717 A.50216726 CTOR CTXR O.11391251 O.21612337 O.41511844 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html <div class="xn-content"> <p class="prntac"><i><money>$7.1 Million</money> in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR</i> <i>^®</i></p><p class="prntac"><i><money>$17 million</money> in cash and cash equivalents as of <chron>June 30, 2026</chron></i></p><p class="prntac"><i>Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended <chron>June 30, 2026</chron>, and provided a business update, including progress at http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html Fri, 14 Aug 2026 16:30:00 -0400 A.24478717 A.50216726 CTOR CTXR O.11391251 O.21612337 O.41511844 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html <div class="xn-content"> <p class="prntac"><i><money>$7.1 Million</money> in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR</i> <i>^®</i></p><p class="prntac"><i><money>$17 million</money> in cash and cash equivalents as of <chron>June 30, 2026</chron></i></p><p class="prntac"><i>Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended <chron>June 30, 2026</chron>, and provided a business update, including progress at http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html Fri, 14 Aug 2026 16:30:00 -0400 A.24478717 A.50216726 CTOR CTXR O.11391251 O.21612337 O.41511844 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html <div class="xn-content"> <p class="prntac"><i><money>$7.1 Million</money> in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR</i> <i>^®</i></p><p class="prntac"><i><money>$17 million</money> in cash and cash equivalents as of <chron>June 30, 2026</chron></i></p><p class="prntac"><i>Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended <chron>June 30, 2026</chron>, and provided a business update, including progress at http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html Fri, 14 Aug 2026 16:30:00 -0400 A.24478717 A.50216726 CTOR CTXR O.11391251 O.21612337 O.41511844 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html <div class="xn-content"> <p class="prntac"><i><money>$7.1 Million</money> in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR</i> <i>^®</i></p><p class="prntac"><i><money>$17 million</money> in cash and cash equivalents as of <chron>June 30, 2026</chron></i></p><p class="prntac"><i>Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended <chron>June 30, 2026</chron>, and provided a business update, including progress at http://www.streetinsider.com/Press+Releases/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html Fri, 14 Aug 2026 16:30:00 -0400 A.24478717 A.50216726 CTOR CTXR O.11391251 O.21612337 O.41511844 O.54377330 http://www.streetinsider.com/PRNewswire/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html <div class="xn-content"> <p class="prntac"><i><money>$7.1 Million</money> in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR</i> <i>^®</i></p><p class="prntac"><i><money>$17 million</money> in cash and cash equivalents as of <chron>June 30, 2026</chron></i></p><p class="prntac"><i>Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended <chron>June 30, 2026</chron>, and provided a business update, including progress at http://www.streetinsider.com/PRNewswire/Citius+Pharmaceuticals%2C+Inc.+Reports+Fiscal+Third+Quarter+2026+Financial+Results+and+Provides+Business+Update/26931297.html Fri, 14 Aug 2026 16:30:00 -0400 A.24478717 A.50216726 CTOR CTXR O.11391251 O.21612337 O.41511844 O.54377330